News

Select Year
Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.
November 2, 2020 4:05 PM
EST
2020
Aurinia Announces Outcome of AUDREY™ Clinical Trial in Dry Eye Syndrome
Download
October 27, 2020 4:05 PM
EDT
2020
Aurinia Announces European Investigator-Initiated Trial to Evaluate Antiviral Activity of Voclosporin in Kidney Transplant Recipients with COVID-19
Download
October 22, 2020 4:15 PM
EDT
2020
Aurinia Presents Voclosporin Efficacy and Pharmacokinetic Data from Integrated Analysis of AURA-LV and AURORA Pivotal Trials at ASN Kidney Week 2020
Download
October 14, 2020 6:05 AM
EDT
2020
Aurinia Pharmaceuticals Announces Launch of Lupus Nephritis Disease-State Awareness Initiative for Healthcare Professionals, TimeIsNephrons.com
Download
October 2, 2020 5:00 PM
EDT
2020
Aurinia Announces New Employment Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Download
September 28, 2020 6:05 AM
EDT
2020
Aurinia Completes Final Patient Treatment in AUDREY Phase 2/3 Clinical Trial of Voclosporin Ophthalmic Solution for Dry Eye Syndrome
Download
September 10, 2020 6:05 AM
EDT
2020
Aurinia Pharmaceuticals to Present at Three Upcoming Virtual Investor Conferences
Download
September 4, 2020 6:04 PM
EDT
2020
Aurinia Announces New Employment Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Download
August 11, 2020 4:02 PM
EDT
2020
Aurinia Reports Second Quarter 2020 Financial Results and Recent Operational Highlights
Download
August 4, 2020 6:05 AM
EDT
2020
Aurinia Pharmaceuticals to Present at the BTIG Virtual Biotechnology Conference
Download
July 30, 2020 6:05 AM
EDT
2020
Aurinia Pharmaceuticals to Report Second Quarter 2020 Financial Results on August 11, 2020
Download
July 27, 2020 10:15 AM
EDT
2020
Aurinia Closes US$200 Million Public Offering of Common Shares
Download
July 22, 2020 11:05 PM
EDT
2020
Aurinia Prices US$200 Million Public Offering of Common Shares
Download
July 22, 2020 4:08 PM
EDT
2020
Aurinia Announces Public Offering of Common Shares
Download
July 21, 2020 5:27 PM
EDT
2020
Aurinia Announces U.S. Food and Drug Administration Acceptance of the Filing of New Drug Application and Priority Review for Voclosporin for the Treatment of Lupus Nephritis
Download
June 22, 2020 6:05 AM
EDT
2020
Aurinia Completes Patient Enrollment Into the AUDREY Phase 2/3 Clinical Trial of Voclosporin Ophthalmic Solution for the Treatment of Dry Eye Syndrome
Download
June 9, 2020 6:05 AM
EDT
2020
Aurinia Presents Additional AURORA Pivotal Trial Safety Data at the ERA-EDTA Virtual Congress 2020
Download
June 5, 2020 7:05 AM
EDT
2020
Aurinia Presents AURORA Pivotal Trial Subgroup Analysis at the EULAR 2020 E-Congress
Download
June 3, 2020 6:05 AM
EDT
2020
Aurinia Announces Results of Annual General Meeting
Download
June 1, 2020 4:05 PM
EDT
2020
Aurinia Pharmaceuticals to Present at the Jefferies Virtual Healthcare Conference
Download
May 26, 2020 6:05 AM
EDT
2020
Aurinia Completes Submission of New Drug Application to the U.S. Food & Drug Administration for Voclosporin for the Treatment of Lupus Nephritis
Download
May 15, 2020 4:05 PM
EDT
2020
Aurinia Pharmaceuticals to Present at 2020 RBC Capital Markets’ Virtual Global Healthcare Conference
Download
May 14, 2020 4:02 PM
EDT
2020
Aurinia Reports First Quarter 2020 Financial Results and Recent Operational Highlights
Download
May 7, 2020 6:05 AM
EDT
2020
Aurinia Pharmaceuticals to Release First Quarter 2020 Financial Results on May 14, 2020
Download
April 27, 2020 6:05 AM
EDT
2020
Aurinia Appoints Joe Miller as Chief Financial Officer
Download
No Results Found
Please try different keywords or filters.

Email Alerts

By providing your email address above, you are providing consent to Aurinia Pharmaceuticals Inc. to send you the requested Investor Email Alert updates. For information on how we protect your information, please refer to our Privacy Policy.
Thank you! Your message has been sent!
Oops! There was an error with your submission.